Statin use, serum lipids, and prostate inflammation in men with a negative prostate biopsy: Results from the reduce trial

Keyphrases

• Confidence Interval 100%
• Serum Lipids 100%
• Statin Use 100%
• Negative Prostate Biopsy 100%
• Prostate Inflammation 100%
• Statins 80%
• Acute Inflammation 80%
• Prostate Cancer Risk 60%
• Inflammation 60%
• Lipids 40%
• Prostate Cancer 40%
• High-density Lipoprotein Cholesterol (HDL-C) 40%
• Chronic Inflammation 40%
• Histologic 40%
• Advanced Prostate Cancer 40%
• Severe Acute 40%
• Triglycerides 20%
• Dutasteride 20%
• Cholesterol 20%
• Logistic Regression 20%
• Inverse Association 20%
• Prostate Biopsy 20%
• Low-density Lipoprotein 20%
• Biopsy Cores 20%
• Anti-inflammatory Properties 20%
• Lipid Levels 20%
• Central Review 20%
• Cholesterol-lowering 20%
• Level of Use 20%

Immunology and Microbiology

• Lipid Blood Level 100%
• Acute Inflammation 100%
• Prostate 50%
• Lipid Level 50%
• High-Density Lipoprotein 50%
• Cholesterol Blood Level 25%
• Low-Density Lipoprotein 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammation 100%
• Statin (Protein) 100%
• Prostate Cancer 41%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 25%
• High Density Lipoprotein 16%
• Chronic Inflammation 16%
• Dutasteride 8%
• Triacylglycerol 8%
• Anti-Inflammatory Drug 8%
• Low Density Lipoprotein Cholesterol 8%